Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study.
To examine gender differences in clinical response to highly active antiretroviral treatment (HAART). A cohort of HIV-positive individuals was examined. Outcomes assessed were hospital admission and disease progression (either a new AIDS diagnosis or death) after starting HAART. Hazard ratios (HRs) derived using Cox regression methods compared female-to-male rates, adjusting for other factors independently associated with outcome. Four hundred ninety-seven men and 146 women were followed up over a median of 13 months after starting HAART. Eighty-one percent of men were white, and 75% were homosexual. Fifty-eight percent of women were black African, and 86% were in the heterosexual risk category. The baseline CD4 count was higher in men than in women (191 vs. 145 x 10; p < .01), but viral loads were similar (5.2 vs. 5.1 log copies/ml, respectively; p = .13). Fifty-six percent of men and women were treatment naïve. Eighteen percent of men and women were admitted during follow-up, with 17% of male admissions and 12% of female admissions being the result of an AIDS-defining illness. The HR for admission was 0.76 (95% confidence interval [CI]: 0.46-1.27; p = .30) for women relative to men. Eleven percent of the men and 8% of the women experienced progression. Eighty-eight percent of progressions were the result of a new AIDS diagnosis (46 in men, 11 in women), and 8 men died. The HR for progression was 0.70 (CI: 0.36-1.33; p = .28). Our results suggest a possible benefit in women compared with men in the rate of outcomes after HAART. Further analysis with longer follow-up or greater numbers would enable a more powerful analysis to be performed.